1
项与 缬沙坦/塞来昔布/二甲双胍 相关的临床试验A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients
Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure, arthritis and inadequate glycemic control with metformin monotherapy, diet and exercise over 26 weeks of treatment.
Objective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to metformin monotherapy.
Hypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR provides greater improvements in glycemic, inflammatory and atherogenic parameters compared to metformin monotherapy.
100 项与 缬沙坦/塞来昔布/二甲双胍 相关的临床结果
100 项与 缬沙坦/塞来昔布/二甲双胍 相关的转化医学
100 项与 缬沙坦/塞来昔布/二甲双胍 相关的专利(医药)
100 项与 缬沙坦/塞来昔布/二甲双胍 相关的药物交易